- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01228838
Study of NGX-1998 for the Treatment of Postherpetic Neuralgia
September 6, 2012 updated by: NeurogesX
A Multicenter Randomized, Double-Blind, Controlled Study to Evaluate Safety, Tolerability and Preliminary Efficacy of Two Capsaicin Concentration Variations of NGX-1998 (10% or 20% w/w) in Subjects With Postherpetic Neuralgia (PHN)
The purpose of this study is to assess the efficacy, safety and tolerability of NGX-1998 applied for 5 minutes for the treatment of postherpetic neuralgia (PHN).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This study is a 12-week multicenter randomized, double-blind, controlled evaluation of the efficacy, safety and tolerability of NGX-1998 for the treatment of postherpetic neuralgia (PHN).
Eligible subjects will have pain from PHN, with average numeric pain rating scale (NPRS) scores during screening of 4 to 9 (inclusive).
Painful areas of up to 1500 cm2 will be treated during a single Test Article application.
Subjects will be randomly assigned to receive NGX-1998 (10% or 20% w/w) or placebo according to an unequal allocation scheme of 2:2:1.
Subjects will also be stratified by gender.
Study Type
Interventional
Enrollment (Actual)
183
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Huntsville, Alabama, United States
- NeurogesX Investigational Site
-
-
Arizona
-
Tucson, Arizona, United States
- NeurogesX Investigational Site
-
-
California
-
Irvine, California, United States
- NeurogesX Investigational Site
-
La Jolla, California, United States
- NeurogesX Investigational Site
-
Napa, California, United States
- NeurogesX Investigational Site
-
San Francisco, California, United States
- NeurogesX Investigational Site
-
Santa Monica, California, United States
- NeurogesX Investigational Site
-
-
Florida
-
New Port Richey, Florida, United States
- NeurogesX Investigational Site
-
North Palm Beach, Florida, United States
- NeurogesX Investigational Site
-
Sarasota, Florida, United States
- NeurogesX Investigational Site
-
St. Petersburg, Florida, United States
- NeurogesX Investigational Site
-
-
Georgia
-
Marietta, Georgia, United States
- NeurogesX Investigational Site
-
-
Idaho
-
Boise, Idaho, United States
- NeurogesX Investigational Site
-
-
Illinois
-
Bloomington, Illinois, United States
- NeurogesX Investigational Site
-
-
Iowa
-
West Des Moines, Iowa, United States
- NeurogesX Investigational Site
-
-
Kansas
-
Kansas City, Kansas, United States
- NeurogesX Investigational Site
-
-
Kentucky
-
Lexington, Kentucky, United States
- NeurogesX Investigational Site
-
-
Louisiana
-
Shreveport, Louisiana, United States
- NeurogesX Investigational Site
-
-
Massachusetts
-
Hyannis, Massachusetts, United States
- NeurogesX Investigational Site
-
-
Michigan
-
Ann Arbor, Michigan, United States
- NeurogesX Investigational Site
-
-
Minnesota
-
Minneapolis, Minnesota, United States
- NeurogesX Investigational Site
-
-
Mississippi
-
Hattiesburg, Mississippi, United States
- NeurogesX Investigational Site
-
-
New York
-
Albany, New York, United States
- NeurogesX Investigational Site
-
Rochester, New York, United States
- NeurogesX Investigational Site
-
-
North Carolina
-
Hickory, North Carolina, United States
- NeurogesX Investigational Site
-
Winston-Salem, North Carolina, United States
- NeurogesX Investigational Site
-
-
Oregon
-
Portland, Oregon, United States
- NeurogesX Investigational Site
-
-
Pennsylvania
-
Altoona, Pennsylvania, United States
- NeurogesX Investigational Site
-
-
Texas
-
San Antonio, Texas, United States
- NeurogesX Investigational Site
-
Webster, Texas, United States
- NeurogesX Investigational Site
-
-
Utah
-
Salt Lake City, Utah, United States
- NeurogesX Investigational Site
-
-
Virginia
-
Richmond, Virginia, United States
- NeurogesX Investigational Site
-
-
Washington
-
Seattle, Washington, United States
- NeurogesX Investigational Site
-
Wenatchee, Washington, United States
- NeurogesX Investigational Site
-
-
Wisconsin
-
Madison, Wisconsin, United States
- NeurogesX Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 90 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Between 18 and 90 years of age, inclusive.
- Diagnosis of PHN with at least six (6) months of pain since shingles vesicle crusting.
- Average NPRS scores for PHN-associated pain during Days -14 to -4 of 4 to 9, inclusive.
- Intact, unbroken skin over the painful area(s) to be treated.
- If taking chronic pain medications, be on a stable (not PRN) regimen for at least 21 days prior to Test Article Application Visit and willing to maintain medications at same stable dose(s) and schedule throughout the study.
- Female subjects with child-bearing potential must have a negative serum beta human chorionic gonadotropin (hCG) pregnancy test, to be performed within 7 days of the Test Article Application Visit.
- All subjects must be willing to use effective methods of birth control and/or refrain from participating in a conception process during the study.
- If breastfeeding, the subject should agree not to breastfeed their child after treatment on the treatment day.
- Be willing and able to comply with protocol requirements for the duration of study participation.
- Subjects must sign an informed consent form for this study approved by the Investigator's Institutional Review Board/Independent Ethics Committee (IRB/IEC).
Exclusion Criteria:
- Concomitant opioid medication, unless orally or transdermally administered and not exceeding a total daily dose of morphine 60 mg/day, or equivalent. Parenteral opioid use is excluded.
- Unavailability of an effective medication for treatment related discomfort for the subject, such as unwillingness to use opioid analgesics during study treatment, or high tolerance to opioids precluding the ability to relieve treatment-associated discomfort.
- Active substance abuse or history of chronic substance abuse within the past year, or prior chronic substance abuse judged likely to recur during the study period.
- Recent use (within 21 days preceding the Test Article Application Visit [Day 0]) of any topically applied pain medication on the painful areas.
- Receipt of Qutenza® within 12 months of the Test Article Application Visit (Day 0). Subjects who have received Qutenza® 12 months or more before Test Article Application Visit (Day 0), and who did not respond should also be excluded.
- Participation in another drug research study within 30 days preceding the Test Article Application Visit (Day 0).
- Current use of any Class I anti-arrhythmic drugs or III anti-arrhythmic drugs.
- Diabetes mellitus, unless well-controlled as evidenced by an HBA1c level less than or equal to nine percent (9%).
- A recent history of cardiovascular or cerebrovascular events or unstable hypertension, unless adequately controlled by medication.
- Significant pain of an etiology other than PHN, for example, compression-related neuropathies, fibromyalgia or arthritis.
- Painful PHN areas located on the face, above the hairline of the scalp, and/or in proximity to mucous membranes.
- Any implanted medical device for the treatment of neuropathic pain.
- History of hypersensitivity to capsaicin, local anesthetics or any components of the CTLs, Cleansing Gel or the lidocaine (2.5%) / prilocaine (2.5%) topical anesthetic cream.
- Patients with glucose-6 phosphate dehydrogenase deficiencies.
- Significant ongoing or untreated abnormalities or conditions, including active malignancy defined as treatment required in the last five (5) years, that in the opinion of the Investigator would interfere with the ability to complete the study or the evaluation of AEs.
- Patients with congenital or idiopathic methemoglobinemia.
- Recent history of a significant medical-surgical intervention in the judgment of the Investigator; examples include but are not limited to major surgery or percutaneous angioplasty/coronary artery stent placement within the past 3 months, and receipt of immunosuppressive therapy within 3 months, prior to the Test Article Application Visit [Day 0].
- Evidence of cognitive impairment including dementia that may interfere with subject's ability to complete daily pain diaries requiring subject's recall of average PHN pain level in the past 24 hours.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: NGX-1998, 10% w/w capsaicin
|
Capsaicin topical liquid to be applied for 5 minutes one time only.
|
Experimental: NGX-1998, 20% w/w capsaicin
|
Capsaicin topical liquid to be applied for 5 minutes one time only.
|
Placebo Comparator: Placebo liquid
|
Placebo topical liquid to be applied for 5 minutes one time only.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percent change from baseline in the "average pain for the past 24 hours" NPRS score during Weeks 2-8.
Time Frame: Weeks 2-8
|
Weeks 2-8
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Absolute change and percent change from baseline in the "average pain for the past 24 hours" NPRS score at Week 8 and 12
Time Frame: Week 8 and Week 12
|
Week 8 and Week 12
|
Absolute change and percent change from baseline in the "average pain for the past 24 hours" NPRS score during Weeks 2-12.
Time Frame: Weeks 2-12
|
Weeks 2-12
|
Proportion of subjects with at least a 30% decrease from baseline in their "average pain for the past 24 hours" NPRS during Weeks 2-8, Weeks 2-12, at Week 8 and Week 12.
Time Frame: Weeks 2-12
|
Weeks 2-12
|
Proportion of subjects with at least a 2 unit decrease from baseline in their "average pain for the past 24 hours" NPRS during Weeks 2-8, Weeks 2-12, at Week 8 and Week 12.
Time Frame: Week 8 and Week 12
|
Week 8 and Week 12
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Trudy Vanhove, MD, PhD, MBA, NeurogesX
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2010
Primary Completion (Actual)
September 1, 2011
Study Completion (Actual)
September 1, 2011
Study Registration Dates
First Submitted
October 25, 2010
First Submitted That Met QC Criteria
October 25, 2010
First Posted (Estimate)
October 27, 2010
Study Record Updates
Last Update Posted (Estimate)
September 10, 2012
Last Update Submitted That Met QC Criteria
September 6, 2012
Last Verified
May 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- C204
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pain
-
Flowonix MedicalApproved for marketingBack Pain | Leg Pain | Trunk Pain | Intractable Pain | Arm Pain
-
University Hospital Schleswig-HolsteinZealand University Hospital; European Regional Development Fund; Design School...CompletedPain, Acute | Pain, Chronic | Pain Measurement | Pain, CancerGermany
-
Dr. Negrin University HospitalCompletedPostoperative Pain, Acute | Postoperative Pain, ChronicSpain
-
George Washington UniversityRecruitingCervical Fusion | Pain, Back | Pain, Neck | Myofacial PainUnited States
-
Dow University of Health SciencesRecruitingLow Back Pain | Chronic Low-back Pain | Low Back Pain, Mechanical | Mechanical Low Back Pain | Pain, Chronic | Pain, Back | Lower Back Pain Chronic | CLBP - Chronic Low Back PainPakistan
-
Universitat Jaume ICompletedPain, Acute | Pain, Chronic | OncologySpain
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Postoperative Pain, Acute | Postoperative Pain, Chronic | VATSTurkey
-
Janssen Research & Development, LLCCompletedPain, Radiating | Pain, Burning | Pain, Crushing | Pain, Migratory | Pain, SplittingUnited States, France, Spain, Poland, Portugal
-
susanne beckerSNSFCompletedLow Back Pain | Pain, Acute | Pain, ChronicSwitzerland
-
University of Campinas, BrazilCompletedPREGNANCY | LUMBAR BACK PAIN | PELVIC PAIN
Clinical Trials on NGX-1998
-
NeurogesXCompletedHIV Infections | Pain | Peripheral Nervous System Diseases
-
NeurogesXCompletedPain | Peripheral Nervous System Diseases | Neuralgia | Herpes Zoster | Shingles
-
Astellas Pharma s.r.o.CompletedPost-operative Peripheral Neuropathic PainCzech Republic
-
NeurogesXCompletedPain | Peripheral Nervous System Diseases | Neuralgia | Herpes Zoster | Shingles